With Type 1 Diabetes Delay Possible, Focus Now on Screening
The FDA approval of teplizumab for the delay of type 1 diabetes highlights the need to cost-effectively identify those at risk who could potentially receive it.
Medscape Medical News
source https://www.medscape.com/viewarticle/984748?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/984748?src=rss
Comments
Post a Comment